KTTA
NASDAQ · Biotechnology
Pasithea Therapeutics Corp
$0.74
-0.04 (-4.88%)
Open$0.75
Previous Close$0.78
Day High$0.78
Day Low$0.74
52W High$3.79
52W Low$0.28
Volume—
Avg Volume145.6K
Market Cap17.96M
P/E Ratio—
EPS$-5.21
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,537.8% upside
Current
$0.74
$0.74
Target
$26.92
$26.92
$19.73
$26.92 avg
$29.00
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 318.0K | 3.90M | 3.72M |
| Net Income | -315,914,244 | 467.4K | 601.6K |
| Profit Margin | -14,394.0% | 12.0% | 16.2% |
| EBITDA | -314,787,800 | 1.16M | 1.10M |
| Free Cash Flow | — | 801.3K | 617.9K |
| Rev Growth | — | +18.2% | +4.0% |
| Debt/Equity | — | 0.89 | 0.81 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |